U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H12O6
Molecular Weight 336.295
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DICUMAROL

SMILES

OC1=C(CC2=C(O)C3=CC=CC=C3OC2=O)C(=O)OC4=CC=CC=C14

InChI

InChIKey=DOBMPNYZJYQDGZ-UHFFFAOYSA-N
InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2

HIDE SMILES / InChI

Molecular Formula C19H12O6
Molecular Weight 336.295
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: https://www.ncbi.nlm.nih.gov/mesh/68001728

Dicumarol is an coumarin-like compound found in sweet clover. It is used as oral anticoagulant and acts by inhibiting the hepatic synthesis of vitamin K-dependent coagulation factors (prothrombin and factors VII, IX, and X). It results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots. Dicumarol is also used in biochemical experiments as an inhibitor of reductases.

Originator

Curator's Comment: Campbell, H.A. & Link, K.P. (1941) Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. Journal of Biological Chemistry, 138, 21–33.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.0 µM [IC50]
10.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
DICUMAROL

Approved Use

For decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.

Launch Date

1944
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
20 μg/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
521 μg × h/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.84 h
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.03%
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 59.8+15.3 years
n = 71
Health Status: unhealthy
Age Group: 59.8+15.3 years
Sex: M+F
Population Size: 71
Sources:
2100 mg single, oral
Overdose
Dose: 2100 mg
Route: oral
Route: single
Dose: 2100 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Disc. AE: Distended blood vessels...
AEs leading to
discontinuation/dose reduction:
Distended blood vessels (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Distended blood vessels 1 patient
Disc. AE
2100 mg single, oral
Overdose
Dose: 2100 mg
Route: oral
Route: single
Dose: 2100 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching.
1996 May 10
Coumarin-based inhibitors of HIV integrase.
1997 Jan 17
Fulminant hepatic failure associated with dicoumarol therapy.
1998 Feb
NRH:quinone oxidoreductase2 (NQO2).
2000 Dec 1
Coumarin derivatives and breast-feeding.
2000 Jun
Phosphorylation is involved in the activation of metal-regulatory transcription factor 1 in response to metal ions.
2001 Nov 9
P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.
2003 Dec 9
Dicoumarol: a unique microtubule stabilizing natural product that is synergistic with Taxol.
2003 Mar 15
Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols.
2005 Apr 1
Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells.
2005 Feb
Dicoumarol relieves serum withdrawal-induced G0/1 blockade in HL-60 cells through a superoxide-dependent mechanism.
2005 Jun 1
Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression.
2006 Aug 1
Molecular cloning of a novel type of rat cytoplasmic 17beta-hydroxysteroid dehydrogenase distinct from the type 5 isozyme.
2006 Jun
Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target.
2007 Dec
The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells.
2009 Jul 15
Analysis of couch position tolerance limits to detect mistakes in patient setup.
2009 Oct 29
Protective effect of sulforaphane against cisplatin-induced mitochondrial alterations and impairment in the activity of NAD(P)H: quinone oxidoreductase 1 and γ glutamyl cysteine ligase: studies in mitochondria isolated from rat kidney and in LLC-PK1 cells.
2010 Nov 10
Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines.
2010 Oct 6
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.
2011 Oct 27
NAD(P)H:quinone oxidoreductase 1 is induced by progesterone in cardiomyocytes.
2012 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
Dicoumarol inhibits rat liver microsomal vitamin K epoxide reductase with IC50=2 uM and cytosolic DT-diaphorase with IC50=0.05 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:06:24 GMT 2023
Edited
by admin
on Fri Dec 15 15:06:24 GMT 2023
Record UNII
7QID3E7BG7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DICUMAROL
HSDB   MI   ORANGE BOOK   USAN   USP-RS   VANDF  
USAN  
Official Name English
dicoumarol [INN]
Common Name English
3,3'-METHYLENEBIS(4-HYDROXYCOUMARIN)
Systematic Name English
DICUMAROL [ORANGE BOOK]
Common Name English
DICOUMAROLUM [WHO-IP LATIN]
Common Name English
DICOUMAROL [WHO-IP]
Common Name English
DICOUMAROL [MART.]
Common Name English
DICUMAROL [USAN]
Common Name English
DICUMAROL [HSDB]
Common Name English
DICOUMAROL
INN   MART.   WHO-DD   WHO-IP  
INN  
Official Name English
NSC-221570
Code English
DICUMAROL [MI]
Common Name English
2H-1-BENZOPYRAN-2-ONE), 3,3'-METHYLENEBIS(4-HYDROXY-
Systematic Name English
NSC-17860
Code English
DICUMAROL [VANDF]
Common Name English
Dicoumarol [WHO-DD]
Common Name English
NSC-41834
Code English
Classification Tree Code System Code
NCI_THESAURUS C45597
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
WHO-VATC QB01AA01
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
NCI_THESAURUS C263
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
WHO-ATC B01AA01
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
Code System Code Type Description
EVMPD
SUB07101MIG
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
DRUG BANK
DB00266
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
NSC
17860
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
HSDB
3223
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
WIKIPEDIA
DICOUMAROL
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
CHEBI
4513
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DICUMAROL
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY Description: A white or creamy white, crystalline powder; odour, characteristic, faint.Solubility: Practically insoluble in water, ethanol (~750 g/l) TS and ether R.Category: Anticoagulant.Storage: Dicoumarol should be kept in a well-closed container, protected from light.Definition: Dicoumarol contains not less than 98.5% and not more than 101.0% of C19H12O6, calculated with reference to the dried substance.
FDA UNII
7QID3E7BG7
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
MESH
D001728
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
NSC
221570
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
PUBCHEM
54676038
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
SMS_ID
100000082921
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
IUPHAR
6808
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
ALANWOOD
dicoumarol
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
INN
2897
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-632-9
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
RXCUI
1598
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1466
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
NSC
41834
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
NCI_THESAURUS
C310
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
CAS
66-76-2
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
DRUG CENTRAL
867
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
MERCK INDEX
m4370
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID8021729
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY